Murine subcutaneous immunotherapy models with beneficial immunological and physiological effects
10.5415/apallergy.2013.3.1.50
- Author:
Yoon Seok CHANG
1
;
Yoon Keun KIM
;
Sae Hoon KIM
;
Heung Woo PARK
;
Kyung Up MIN
;
You Young KIM
;
Sang Heon CHO
Author Information
1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Medical Research Center, Seoul 110-744, Korea. shcho@plaza.snu.ac.kr
- Publication Type:Original Article
- Keywords:
Asthma;
Animal models;
Allergy;
Immunotherapy
- MeSH:
Animals;
Appointments and Schedules;
Asthma;
Humans;
Hypersensitivity;
Immunoglobulin E;
Immunoglobulin G;
Immunotherapy;
Inflammation;
Interleukin-5;
Mice;
Models, Animal;
Ovalbumin;
Ovum
- From:
Asia Pacific Allergy
2013;3(1):50-58
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Immunotherapy was introduced 100 years ago and has a unique role in the treatment of allergic diseases in that only immunotherapy can induce long-term immunological tolerance. However, only a few mouse models of immunotherapy have been developed so far. OBJECTIVE: We tried to establish murine immunotherapy models that have similar findings in human using subcutaneous rush immunotherapy-like schedule. METHODS: To determine the maximal safe or maximal tolerable dose, injection dose was doubled twice a day from the dose of sensitization. Mice with established asthma using ovalbumin (OVA) were repeatedly injected with OVA from the dose of sensitization subcutaneously twice a day: after reaching to the maximal safe or maximal tolerable dose, mice were injected with each dose either 10 times or 24 times. RESULTS: Short term immunotherapy (10 times) with the maximal safe and tolerable dose of OVA showed decreased IL-5 production, decreased IL-5/INF-γ ratio, and increased IgG2a/IgG1 but there was no significant difference in airway hyperresponsiveness (AHR) or airway inflammation. Prolonged immunotherapy (24 times) with the maximal tolerable dose not only decreased cytokine productions of IL-5 and even INF-γ, but also decreased IgE, IgG1 and even IgG2a production. Remarkably, the prolonged immunotherapy provided a protective effect on AHR. CONCLUSION: This study suggested immunotherapy models with some beneficial immunological and physiological effects in murine asthma.
